The phase III EMBRACA trial was an open-label, randomized trial, comparing talazoparib versus choice of standard chemotherapy of the physician (capecitabine, eribulin, gemcitabine, or vinorelbine) in pretreated locally advanced (not amenable to curative treatment) or metastatic BRCA1/2 mutated breast cancer (36). This evidence concerns the gene BRCA1 and breast carcinoma.